Identifiable Intangible Assets

3 Months Ended

Mar. 31, 2019

NOTE 6 – Identifiable intangible assets:

Identifiable intangible assets consisted of the following:

	Gross carrying amount net of impairment				Accumulated amortization				Net carrying amount
	March 31,		December 31,		March 31,		December 31,		March 31,		December 31,
	2019		2018		2019		2018		2019		2018
	(U.S. $ in millions)
Product rights	$	20,201	$	20,361	$	9,706	$	9,565	$	10,494	$	10,796
Trade names		603		606		100		91		503		515
In process research and development		2,193		2,694		—		—		2,193		2,694
Total	$	22,997	$	23,661	$	9,806	$	9,656	$	13,191	$	14,005

Product rights and trade names

Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately 12 years. Amortization of intangible assets amounted to $283 million and $310 million in the three months ended March 31, 2019 and 2018, respectively.

IPR&D

Teva’s IPR&D are assets that have not yet been approved in major markets. Teva’s IPR&D is comprised mainly of the following acquisitions and related assets: various generic products (Actavis

Generics) –

$1,935 million; various generic products (Rimsa

) –

$47 million and

AUSTEDO –

$211 million. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods.

In the first three months of 2019, Teva reclassified $236 million of products from IPR&D to product rights following regulatory approval, mainly $174 million in connection with Methyl ER.

Intangible assets impairment

Impairments of long-lived intangible assets in the

first three months of

2019 and 2018 were $469 million and $206 million, respectively. Impairments in the first quarter of 2019 consisted of:

IPR&D assets of $265 million, mainly due to: (i) $125 million related to lenalidomide (generic equivalent of Revlimid

) due to modified competition assumptions as a result of settlements between the innovator and other generic filers and (ii) $140 million of other generic products acquired from Actavis Generics due to development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date or discount rate); and

Identifiable product rights of $204 million, mainly due to updated market assumptions regarding price and volume of products acquired from Actavis Generics and primarily marketed in the United States.